LYEL Valuation

Lyell Immunopharma Inc (LYEL) has a current Price-to-Book (P/B) ratio of 2.02. Compared to its 3-year average P/B ratio of 0.71 , the current P/B ratio is approximately 182.56% higher. Relative to its 5-year average P/B ratio of 1.18, the current P/B ratio is about 71.38% higher. Lyell Immunopharma Inc (LYEL) has a Forward Free Cash Flow (FCF) yield of approximately -22.64%. Compared to its 3-year average FCF yield of -52.77%, the current FCF yield is approximately -57.10% lower. Relative to its 5-year average FCF yield of -38.76% , the current FCF yield is about -41.59% lower.